Collegium Reports First Quarter 2020 Profitability
May 07, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020 – – Non-GAAP Net Income of $31.2 Million in the First Quarter of 2020 – – Xtampza® ER Prescriptions Grew...
Collegium to Host Conference Call to Discuss First Quarter 2020 Financial Results and Provide Corporate Update
April 23, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...
Collegium to Participate in Upcoming Investor Conference
April 07, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
February 27, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
– 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% – – Xtampza® ER Prescriptions Grew 49% in 2019 – – Collegium Guides to Profitability in 2020 – – Conference Call Scheduled...
Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Provide Corporate Update
February 26, 2020 13:05 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Announces Closing of the Nucynta Franchise Acquisition
February 13, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option – – Collegium will Host Conference Call to Discuss Fourth Quarter 2019 Financial...
Collegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes Offering
February 10, 2020 19:14 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625%...
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
February 10, 2020 07:20 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000...
Collegium to Acquire U.S. Rights to Nucynta Franchise
February 06, 2020 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Financially Transformative Acquisition – – Expected to Significantly Grow Net Income, EBITDA and Operating Cash Flows – – Structure of the Financing Allows for Rapid De-Leveraging – –...
Collegium Provides 2020 Financial Guidance
January 07, 2020 16:05 ET
|
Collegium Pharmaceutical, Inc.
– Xtampza® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 – STOUGHTON, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a...